Related Experiment Video
Updated: Mar 11, 2026
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer
Patricia Pautier1, Ignace Vergote, Florence Joly
1*Gustave Roussy Cancer Campus, Villejuif, France; †Leuven Cancer Institute, Leuven, Belgium; ‡Centre François Baclesse, Caen, France; §Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; ‖Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland; ¶Leeds Cancer Centre, St James University Hospital, Leeds, United Kingdom; #City Clinical Oncology Dispensary, St Petersburg, Russia; **Gartnavel General Hospital, Glasgow, United Kingdom; ††Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; ‡‡Vilnius University Institute of Oncology, Vilnius, Lithuania; §§Oncology Centre of Latvia, Riga East University Hospital, Riga, Latvia; ‖‖Ipsen Innovation, Les Ulis, France; and ¶¶Clatterbridge Cancer Centre, University of Liverpool, Bebington, Merseyside, United Kingdom.
Objective:
Advanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as a therapeutic target in patients with endometrial cancer.
Methods:
This was a phase 2, multicenter, international, open-label, randomized (1:1), 2-arm study of the STS inhibitor oral irosustat 40 mg/d versus oral megestrol acetate 160 mg/d in women with advanced/metastatic or recurrent estrogen receptor-positive endometrial cancer. The primary end point was the proportion of patients without progression or death 6 months after start of treatment. Secondary end points included progression-free survival, time to progression, overall survival, and safety.
Results:
Seventy-one patients were treated (36 with irosustat, 35 with megestrol acetate). The study was prematurely stopped after futility analysis. Overall, 36.1% and 54.1% of patients receiving irosustat or megestrol acetate had not progressed or died at 6 months, respectively. There were no statistically significant differences between irosustat and megestrol acetate in response and overall survival rates. Irosustat patients had a median progression-free survival of 16 weeks (90% confidence interval, 9.0-31.4) versus 40 weeks (90% confidence interval, 16.3-64.0) in megestrol acetate patients. Treatment-related adverse events occurred in 20 (55.6%) and 13 (37.1%) patients receiving irosustat or megestrol, respectively. Most adverse events in both groups were grade 1 or 2.
Conclusions:
Although irosustat monotherapy did not attain a level of activity sufficient for further development in patients with advanced/recurrent endometrial cancer, this study confirms the activity of hormonal treatment (megestrol acetate) for this indication.
More Related Videos
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019